Today's guest post is by Pete Salzmann, VP, Immunology at Lilly.
During my training as a physician at the University of California, San Francisco, I often worked with patients facing conditions that were difficult to diagnose and challenging to treat. At the time – the mid-1990s -- remission was particularly elusive for people with rheumatic diseases such as rheumatoid arthritis (RA).